Inclusion criteria:  Have started methotrexate less than 540 days after RA debut. Have used methotrexate for more then 30 days but less than 540 days before study treatment start. Have a baseline DAS28-ESR of more than 3.2 at study treatment start. Were residents of Sweden within 5 years before study treatment start  Exclusion criteria:  Have used other DMARDs (antirheumatic drugs) than methotrexate before treatment start Have initiated study treatments later than May 2020